Clinical Policy: Etanercept (Enbrel)
Customize your policy alerts
Sign up for Peach State Health Plan Policy CP.PHAR.250 alerts
Get alerted when Policy CP.PHAR.250 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, prior authorization, and utilization rules for etanercept (Enbrel) for Peach State Health Plan (Medicaid) members across labeled rheumatologic and dermatologic indications.
Per July SDC, added criteria requiring use of one adalimumab product and listed multiple preferred adalimumab products for all indications.
2Q 2025 review removed minimum cJADAS-10 > 8.5 requirement for pJIA initial criteria and removed requirement for decrease in cJADAS-10 for continued therapy.
Extended initial approval durations to 12 months for chronic conditions.
2Q 2026 annual review: no significant changes; references reviewed and updated.
Coverage Criteria Summary
Initial Therapy — Ankylosing Spondylitis
Covered when ALL of the following are met
Prior authorization may be required for adalimumab products and tofacitinib/tofacitinib XR
Initial Therapy — Plaque Psoriasis
Covered when ALL of the following are met
Prior authorization may be required for adalimumab and ustekinumab products
Initial Therapy — PJIA
Covered when ALL of the following are met
Prior authorization may be required for adalimumab products, Actemra, and tofacitinib
Initial Therapy — Psoriatic Arthritis
Covered when ALL of the following are met
Prior authorization may be required for adalimumab, Otezla, ustekinumab, and tofacitinib products
Initial Therapy — Rheumatoid Arthritis
Covered when ALL of the following are met
Prior authorization may be required for adalimumab products, Actemra, and tofacitinib/tofacitinib XR
Other / Off-label pathway
Other uses
Continued Therapy — Continuation authorized when ALL of the following are met
Continuation authorized when ALL of the following are met
Combination therapy with other biologic disease‑modifying antirheumatic drugs (bDMARDs) or potent immunosuppressants is not authorized. This includes, but is not limited to, concurrent use with other tumor necrosis factor (TNF) antagonists, interleukin pathway inhibitors, Janus kinase inhibitors (JAKi), anti‑CD20 agents, selective co‑stimulation modulators, integrin receptor antagonists, tyrosine kinase 2 inhibitors, and sphingosine‑1‑phosphate receptor modulators due to additive immunosuppression and increased risk of neutropenia and serious infections.
Non‑FDA‑approved indications not specifically addressed in this Etanercept (Enbrel) policy are excluded from coverage unless there is sufficient documentation of efficacy and safety consistent with the Peach State off‑label use policy CP.PMN.53 (Medicaid) or other applicable evidence‑of‑coverage documents.
Etanercept is contraindicated in patients with sepsis. The policy also highlights boxed warnings for serious infections and malignancies, which should be considered when evaluating suitability for therapy.
Historical revisions to the policy reiterate the prohibition on combination use of etanercept with another biologic DMARD or a JAK inhibitor. This requirement was carried forward into Sections I and II during prior annual reviews and template updates to emphasize single‑agent biologic use.
Requests for combination therapy with other bDMARDs or JAK inhibitors will be considered not medically necessary because of additive immunosuppression and the associated increased risk of serious infections and neutropenia.
The policy reiterates that combination use with another biologic DMARD or a JAK inhibitor is not allowed; this prohibition has been explicitly restated in revision notes and applied across indicated sections.
Inclusion or exclusion of procedure and supply codes in this policy does not by itself guarantee coverage. Providers must refer to the specific indication‑level not‑medically‑necessary statements elsewhere in the policy and use current professional coding guidance when submitting claims.
Initial Therapy — Indication Specific
Initial therapy — Indication-specific initial therapy criteria require diagnosis, specialist involvement, age minimums, prior therapy failures or contraindications
Indication-specific initial therapy criteria require diagnosis, specialist involvement, age minimums, prior therapy failures or contraindications
See Sections I.A–I.E for full per‑indication logic
Initial therapy — Aligned with FDA dosing and policy sequencing preferences
Aligned with FDA dosing and policy sequencing preferences
Appendix I contains dosing tables; revisions in Coding Implications note preferred-agent sequencing (chunk 37).
Initial therapy updates — Initial therapy updates captured in revision notes
Initial therapy criteria updates captured in revision notes
Policy-wide change noted in revisions (chunk 41).
2Q 2025 update referenced in revisions (chunk 39/41).
Dosing/Indication-specific coverage
Covered when dosing and indication align with labeled regimens and policy-preferred sequencing for indicated conditions.
chunk 32
chunk 32
chunk 32
chunk 32
chunk 32
Notable coverage criteria updates
Policy-level coverage direction and notable criteria changes include:
applies across indications as specified in Section I
policy-wide change noted in revisions (chunk 41)
Appendix I updated per 2019 ACR guidance
Continued Therapy Requirements
Continued therapy — Continued therapy requirements
Continued therapy requirements
Continuation therapy — Allowed when prior response and safety monitoring show continued benefit and dosing remains within labeled limits
Continuation is allowed when prior response and safety monitoring show continued benefit and dosing remains within labeled limits
chunks 27,37
pJIA continued therapy changes
Continued therapy criteria updated for pJIA
2Q 2025 revision noted in Coding Implications (chunk 39)
Step Therapy and Required Prior Trials
| Step description | Required prior trials / preferences |
|---|---|
| Progressive step prior to Enbrel initiation | |
| Documented failure or intolerance of conventional therapies (examples: ≥2 NSAIDs each ≥4 weeks for AS; ≥3 months of methotrexate or another conventional DMARD where specified), followed by failure of specified biologic(s) or small molecules as listed for the indication (e.g., failure of one adalimumab product unless history of failure of two TNF blockers; trial of tofacitinib/tofacitinib XR when indicated). |
| Policy change | Effect on prior trials for certain indications |
|---|---|
| July SDC: added requirement to use specified preferred agents prior to etanercept for some indications | |
| Examples: AS — required use of Taltz and Xeljanz/XR (per July SDC); PsO — required use of Taltz; pJIA — required use of Actemra and Xeljanz/XR; PsA — required use of Otezla, Taltz, Xeljanz/XR (note: some of these requirements were later removed or modified per subsequent SDC updates). |
| Revision summary | Adalimumab preference / required trial |
|---|---|
| Per July SDC and subsequent updates, policy operationalized adalimumab-class preference and redirection across indications. | |
| Requirement: failure of ONE adalimumab product (examples listed as preferred: Yusimry, Hadlima, unbranded adalimumab-fkjp, unbranded adalimumab-adaz, adalimumab-adbm, Simlandi, adalimumab-aaty) is required in many indications unless member has history of failure of two TNF blockers; prior authorization may be required for adalimumab products. |
Provider Actions and Documentation Requirements
Prior authorization required for Enbrel and certain comparators
Prior authorization is required for etanercept (Enbrel) per the policy and prior authorization may also be required for certain referenced comparator products (for example, adalimumab products, tofacitinib/tofacitinib XR, Actemra, ustekinumab, Otezla) as noted in indication-specific criteria. Providers should follow indication-specific submission requirements when requesting authorization.
- Prior authorization may be required for adalimumab products and tofacitinib/tofacitinib XR (AS) [[see policy notes in chunks 4, 7].]
- Prior authorization may be required for adalimumab and ustekinumab products for PsO (chunk 5).
- Prior authorization may be required for adalimumab products, Actemra, and tofacitinib for PJIA and RA (chunks 7, 11).
Reference J1438 for physician‑administered etanercept
When etanercept is administered by a physician in a supervised setting, providers should reference HCPCS code J1438 on authorization and claims and submit clinical justification consistent with dosing, contraindications, and therapeutic alternative use.
Initial authorization duration and HCPCS code
Initial authorizations for chronic indications have been extended to 12 months. The policy lists J1438 as the HCPCS code for the 25 mg etanercept injection (informational) to be used when the drug is physician‑administered.
- Approval duration for initial and continued therapy for chronic conditions: 12 months (chunks 4, 7, 8, 9, 11 and revision notes in chunk 41).
- J1438 = Injection, etanercept, 25 mg (may be used when administered under direct physician supervision) (chunk 36).
Document required prior trials and durations
Many indications require documented failure of specified prior therapies before Enbrel is authorized; required prior trials and minimum durations are indication‑specific and must be documented.
- Examples: failure of ≥2 NSAIDs each ≥4 weeks for AS (chunk 4); failure of ≥3 months of MTX for PsO and RA (chunks 5, 11).
- Many indications require failure of one adalimumab product (unless history of failure of two TNF blockers) and trials of other specified agents (chunks 4, 7, 9, 11).
Follow preferred‑agent and step‑preference requirements
The policy includes preferred‑agent and step‑preference language requiring use of specified preferred agents for some indications; providers must follow the policy’s required sequence when requesting authorization.
- Per SDC updates, the policy requires use of one adalimumab product and lists preferred adalimumab products across indications (chunk 37).
- Specific preferred agents were added for certain indications (examples in chunk 37 and Appendix B in chunk 21).
Required trial/use of preferred agents before Enbrel in some indications
For certain indications, the policy now requires trial or use of specified preferred agents (for example, adalimumab products) prior to authorization of etanercept; document prior use or failure as specified.
- Policy revisions require trial/use of one adalimumab product and list multiple preferred adalimumab examples (chunk 37).
- Some indications previously required specific preferred agents (Taltz, Xeljanz, Otezla) though subsequent SDC changes have modified these requirements (chunk 41).
Submit supportive clinical documentation with authorization request
Providers must submit supporting clinical documentation (such as office chart notes, lab results, or other clinical information) demonstrating that the member meets all approval criteria when requesting authorization.
- Documentation must support diagnosis, prior therapy trials/failures, specialist involvement, and clinical response or disease activity measures where required (chunk 3).
- pJIA documentation requirements were modified in 2Q2025; see Appendix I for updated disease activity information (chunk 39/37).
Document dosing and product formulation details
When requesting authorization, document the dosing regimen and product formulation (for example, SC prefilled syringe, autoinjector, vial sizes) and indicate the exact dose and frequency being requested.
- Appendix I lists available product presentations (25 mg/0.5 mL prefilled syringe, 50 mg/mL autoinjector, 25 mg vial, etc.) and labeled dosing by indication (chunk 33, chunk 32).
- Ensure submitted dosing aligns with labeled regimens (examples: 50 mg SC once weekly; pediatric 0.8 mg/kg once weekly) (chunk 32).
pJIA documentation changes — updated Appendix I and removed cJADAS‑10 threshold
For polyarticular juvenile idiopathic arthritis (pJIA), the policy removed the prior requirement to document a minimum cJADAS‑10 > 8.5 in the initial criteria and updated Appendix I disease activity information per 2019 ACR guidance; follow the revised Appendix I when documenting pJIA disease activity.
- 2Q 2025 review removed minimum cJADAS‑10 > 8.5 requirement and removed requirement for decrease in cJADAS‑10 for continued therapy; see Appendix I for updated scoring guidance (chunks 39, 32).
Denial risk: missing documentation or requests for combination biologic/JAK therapy
Requests that do not include documentation demonstrating that the member has met all approval criteria, or requests for combination use with other biological DMARDs or JAK inhibitors, will be denied as not authorized.
- Combination use with bDMARDs or other potent immunosuppressants (including TNF antagonists, interleukin agents, and JAK inhibitors) is not authorized (chunk 16).
- Provider submissions must document all required prior trials, contraindications/intolerances, and specialist involvement as applicable (chunk 3).
Coding does not guarantee coverage — verify coding guidance before claims
Inclusion or exclusion of codes in the policy does not guarantee coverage; providers should reference the most up‑to‑date professional coding guidance prior to claim submission and ensure claims use current coding.
- Coding referenced in this policy is informational only; verify coding guidance before submitting claims (chunk 36).
- J1438 may be used when drug is physician‑administered under direct supervision; it is not for self‑administered use (chunk 36).
Confirm coding and claim submission guidance
Before submitting claims, providers should verify current coding guidance and confirm that the HCPCS/CPT/other codes used for etanercept and related services are appropriate, as inclusion in the policy is informational and not a guarantee of reimbursement.
- Providers should reference the most up‑to‑date sources of professional coding guidance prior to claim submission (chunk 36).
Coding and Billing References
| J1438 | Injection, etanercept, 25 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self‑administered) |
| J1438 | Injection, etanercept, 25 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered) |
Use J1438 for physician‑supervised office administration
When etanercept is administered under direct physician supervision in the office setting, J1438 may be used; coding and site-of-care assumptions differ for self-administered dosing.
J1438 use for physician‑administered etanercept (not self‑administered)
J1438 may be used for physician‑administered etanercept under direct supervision in office or infusion center settings; it should not be used for self‑administered dosing.
Biosimilar and Class-Level Preferred Agent Direction
Preferred adalimumab biosimilars listed; trial required
The policy lists multiple preferred adalimumab biosimilars and notes that failure of one adalimumab product is required in many indications unless the member has a history of failure of two TNF blockers.
- Preferred adalimumab examples include Hadlima, Simlandi, Yusimry, adalimumab-aaty, adalimumab-adaz, adalimumab-adbm, and adalimumab-fkjp.
Policy requires use of one adalimumab product (preferred examples listed)
Per SDC updates, the policy added criteria requiring use of one adalimumab product and lists specific adalimumab reference/biosimilar examples as preferred agents for certain indications.
Adalimumab class-level preferred-agent requirement
At the class level, the policy requires trial or use of one adalimumab product and provides preferred examples (e.g., Yusimry, Hadlima, adalimumab-adbm, Simlandi, unbranded adalimumab products) to be tried or used prior to redirection for specified indications.
Definitions and Scoring
Quantity Limits and Typical Dosing
Site of Care and Administration
Office administration coding note (J1438)
When etanercept is administered under direct physician supervision in an office setting, J1438 may be used; self-administered dosing requires different coding and site-of-care assumptions.
Office/infusion center coding implication for J1438
J1438 may be used for physician‑administered etanercept under direct supervision in office or infusion center settings but is not appropriate for self‑administered use.
Background
Etanercept (Enbrel) is a tumor necrosis factor (TNF) blocker indicated for several inflammatory rheumatologic and dermatologic conditions including rheumatoid arthritis, psoriatic arthritis (including juvenile forms), ankylosing spondylitis, plaque psoriasis, and polyarticular juvenile idiopathic arthritis. The policy aligns authorization with indication‑specific dosing regimens and prior‑therapy sequencing consistent with labeled use.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.